Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of LY3372993 in Alzheimer's Disease and Healthy Participants
jRCT2031210492Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of remternetug in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of participants with one or more serious adverse events related to study drug administration. Started Jan 2022; status: active, not recruiting.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on jRCT2031210492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210492.